Ovarian Cancer | Specialty

The ovarian cancer condition center is a comprehensive resource for clinical news and expert insights on ovarian cancer. Read more at OncLive.

Dr Lynam on the Significance of Mirvetuximab Soravtansine in Ovarian Cancer

October 8th 2025

Sarah Lynam, MD, discusses the significance and implications of mirvetuximab soravtansine for the treatment of patients with ovarian cancer.

CDK4/6 Inhibition With Palbociclib Displays Activity in Low-Grade Serous Ovarian Cancer

October 7th 2025

CDK4/6 inhibition with palbociclib demonstrated encouraging efficacy in patients with low-grade serous ovarian cancer.

Poll: Vote on the Top Gynecologic and GI Cancer Abstracts/Topics to Watch at ESMO 2025

October 6th 2025

Vote on the top abstracts and topics to watch in gynecologic and gastrointestinal oncology during the 2025 ESMO Congress.

Advances in Targeted Therapies and ADCs in Gynecologic Cancer Are Highly Anticipated at the 2025 ESMO Congress

October 1st 2025

Experts in the gynecologic cancer landscape highlight their most anticipated presentations ahead of the 2025 ESMO Congress.

Stenoparib Monotherapy Yields Potential OS Benefit in Platinum-Resistant Ovarian Cancer

September 26th 2025

Stenoparib monotherapy generated long-term clinical benefit in patients with platinum-resistant and -refractory advanced ovarian cancer.

Avantect Multi-Cancer and Ovarian Cancer Detection Tests Achieve UKCA Marking

September 25th 2025

A United Kingdom Conformity Assessed marking was granted to the Avantect Multi-Cancer Detection Test and Avantect Ovarian Cancer Test.

Five Under 5: Top Oncology Videos for the Week of 9/14

September 21st 2025

The top 5 OncLive TV videos of the week cover insights in lung cancer, multiple myeloma, and ovarian cancer.

The OncFive: Top Oncology Articles for the Week of 9/14

September 20th 2025

The FDA held a Type A meeting for RP1 in advanced melanoma, the AACR released its Annual Cancer Progress Report, and more.

Dr Lorusso on the Rationale for Investigating Relacorilant Plus Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer

September 18th 2025

Domenica Lorusso, MD, PhD, details the rationale for the ROSELLA trial, evaluating relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer.

Rezatapopt Elicits Responses in Several Solid Tumors Harboring a TP53 Y220C Mutation

September 15th 2025

Updated PYNNACLE data show activity of rezatapopt in TP53 Y220C–mutated solid tumors.

FDA Grants Breakthrough Therapy Designation to R-DXd in CDH6-Expressing Ovarian Cancer

September 15th 2025

Raludotatug deruxtecan earned FDA breakthrough designation for CDH6-expressing platinum-resistant ovarian cancers after bevacizumab treatment.

The OncFive: Top Oncology Articles for the Week of 9/7

September 13th 2025

The FDA has approved TAR-200 in urothelial cancer and selumetinib in pediatric NF-1–associated inoperable plexiform neurofibromas, and more.

Rucaparib Maintenance Yields PFS Benefit Across HRD-Negative Subgroups of High-Grade Ovarian Cancer

September 12th 2025

Vanda Salutari, MD, discusses the efficacy of first-line rucaparib maintenance therapy in patients with HRD-negative high-grade, advanced ovarian cancer.

Evolving Surgical Strategies and the Role of Mirvetuximab Soravtansine Shape the Ovarian Cancer Treatment Paradigm

September 11th 2025

Ryan M. Kahn, MD, MHS, FACOG, discusses the evolution of surgical techniques and practice-changing treatments in the ovarian cancer treatment paradigm.

Dr Moore on the Present Standing of PARP Inhibitors in Ovarian Cancer

September 10th 2025

Kathleen N. Moore, MD, MS, discusses the use of PARP inhibitors in patients with ovarian cancer.

Relacorilant NDA Is Under FDA Review for Platinum-Resistant Ovarian Cancer

September 10th 2025

The FDA accepted a NDA for relacorilant in platinum-resistant ovarian cancer based on data from ROSELLA and other phase 2 trials.

Lunresertib and Other PKMYT1 Inhibitors Show Promise in Gynecologic Malignancies

September 5th 2025

Alison Schram, MD, discusses the potential clinical utility of PKMYT1-targeted agents in gynecologic malignancies.

Dr Kahn on Recognizing Surgical Limitations in Advanced Ovarian Cancer During Ovarian Cancer Awareness Month

September 4th 2025

Ryan Matthew Kahn, MD, MHS, FACOG, discusses the importance of recognizing surgical limitations in the treatment of patients with advanced ovarian cancer.

Health Canada Approves Mirvetuximab Soravtansine for FRα+ Platinum-Resistant Epithelial Ovarian Cancer

September 3rd 2025

Health Canada approved mirvetuximab soravtansine for folate receptor-alpha positive, platinum-resistant epithelial ovarian cancer.

Five Under 5: Top Oncology Videos for the Week of 8/24

August 31st 2025

The top 5 OncLive videos of the week cover insights in lung cancer, ovarian cancer, breast cancer, and prostate cancer.